| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; mouse; fig s4
| Kritikou J, Dahlberg C, Baptista M, Wagner A, Banerjee P, Gwalani L, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636 pubmed publisher |
- western blot; human; 1:500; fig 1
| Marzesco A, Flötenmeyer M, Bühler A, Obermüller U, Staufenbiel M, Jucker M, et al. Highly potent intracellular membrane-associated A? seeds. Sci Rep. 2016;6:28125 pubmed publisher |
- western blot; mouse; fig 6c
| Krysiak K, Tibbitts J, Shao J, Liu T, Ndonwi M, Walter M. Reduced levels of Hspa9 attenuate Stat5 activation in mouse B cells. Exp Hematol. 2015;43:319-30.e10 pubmed publisher |
- western blot; human; 0.25 ug/mL
| Gu L, Talati P, Vogiatzi P, Romero Weaver A, Abdulghani J, Liao Z, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014;13:1246-58 pubmed publisher |
| Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, et al. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell. 2019;36:123-138.e10 pubmed publisher |
| Yang B, Wang K, Wan S, Liang Y, Yuan X, Dong Y, et al. TCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune Diseases. Cell Rep. 2019;27:3629-3645.e6 pubmed publisher |
| Lun X, Szklarczyk D, Gábor A, Dobberstein N, Zanotelli V, Saez Rodriguez J, et al. Analysis of the Human Kinome and Phosphatome by Mass Cytometry Reveals Overexpression-Induced Effects on Cancer-Related Signaling. Mol Cell. 2019;74:1086-1102.e5 pubmed publisher |
| Mann E, Gabryšová L, Pfeffer P, O GARRA A, Hawrylowicz C. High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17+IL-10+ Memory CD4+ T Cell Response towards a Single IL-10-Producing Phenotype. J Immunol. 2019;202:684-693 pubmed publisher |
| Fistonich C, Zehentmeier S, Bednarski J, Miao R, Schjerven H, Sleckman B, et al. Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development. J Exp Med. 2018;215:2586-2599 pubmed publisher |
| Davies R, Hammenfors D, Bergum B, Vogelsang P, Gavasso S, Brun J, et al. Aberrant cell signalling in PBMCs upon IFN-α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature. Eur J Immunol. 2018;48:1217-1227 pubmed publisher |
| Maseda D, Johnson E, Nyhoff L, Baron B, Kojima F, Wilhelm A, et al. mPGES1-Dependent Prostaglandin E2 (PGE2) Controls Antigen-Specific Th17 and Th1 Responses by Regulating T Autocrine and Paracrine PGE2 Production. J Immunol. 2018;200:725-736 pubmed publisher |
| Carpenter A, Wohlfert E, Chopp L, Vacchio M, Nie J, Zhao Y, et al. Control of Regulatory T Cell Differentiation by the Transcription Factors Thpok and LRF. J Immunol. 2017;199:1716-1728 pubmed publisher |
| Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed publisher |
| Novotny Diermayr V, Hart S, Goh K, Cheong A, Ong L, Hentze H, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2012;2:e69 pubmed publisher |
| Hart S, Goh K, Novotny Diermayr V, Tan Y, Madan B, Amalini C, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011;1:e44 pubmed publisher |
